ClinicalTrials.gg
CompletedNCT05420805Biotics_RTTUpdated Apr 18, 2023

Protective Role of Pre-/ Post-biotics on Gut Inflammation, Dysbiosis, and Life Quality in Rett Syndrome (Biotics_RTT)

An interventional study of ALAC, inulin, FOS, and sodium butyrate and Sodium butyrate and zinc oxide in Rett Syndrome, Dysbiosis and Epilepsy, sponsored by Azienda Ospedaliera Universitaria Senese. Completed at 1 site in Italy. Open to female participants aged 3 Years and older. Per ClinicalTrials.gov, last updated 2023-04-18.

Sponsored by Azienda Ospedaliera Universitaria Senese · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
3 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Rett Syndrome with a site in Italy — 3 open to participants now, 3 under way, 1 of them phase 3. Rett Syndrome · Italy.

Started
2022
with 1 other
No phase
4 of 11
none open now
Registered
6th of 11
by date
Lead sponsor
1 of 11
Azienda Ospedaliera Universitaria Senese

Among the 11 studies in Rett Syndrome with a site in Italy, this one is one of 2 that started in 2022, is one of 4 with no phase, and was the 6th registered.

Rett Syndrome

96 studies on the registry are indexed under Rett Syndrome; 19 are open to participants now.

Browse Rett Syndrome studies →

Open to participants now

3 of the 11 studies in Rett Syndrome with a site in Italy are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 14 Rett Syndrome studies recruiting now, 4 (29%) set no upper age limit and 7 (50%) stop at 75 or younger; 12 take children under 18; 3 take healthy volunteers.

This study: 3 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Rett Syndrome with a site in Italy, or all of them as a file.
02

Study summary

The study will examine the potential efficacy and safety of two pre- and post-biotics on markers for gut inflammation and intestinal microbiota ecology in patients with Rett syndrome. Moreover, this trial will search for possible effects on epileptogenesis and quality of life.

Read the detailed description

The gastrointestinal tract is the major site of exposure to environmental molecules where 1) dietary components are chemically transformed by the microbiota, and 2) gut-derived metabolites are disseminated to all organs, including the brain. The human gut microbiota directly affects human health, and its alteration can lead to gastrointestinal abnormalities and inflammation. Indeed, accumulating clinical and experimental evidences indicate that the gut microbiota impacts behavior, modulates neurotransmitter production in the gut and brain, influences brain development and myelination patterns. Specific gut-derived metabolites, such as 4-ethylphenyl sulfate (4-EPS) and isoamylamine (IAA) are known to alter brains activity and anxiety behavior in mice and/ or promoting neural cell death leading to cognitive decline. Rett syndrome (RTT; Online Mendelian Inheritance in Man, OMIM number #312750) is a severe and progressive neurological disorder that almost exclusively affects females with an incidence of \~1:10,000 live births. Loss-of-function mutations of the X-linked methyl-CpG binding protein 2 (MeCP2) gene is the major cause (approximately 90 %) of classical cases of RTT. Although a rare disorder, RTT represents a leading cause of severe cognitive impairment in the female gender. Affected individuals commonly show a period of apparent early normal development, followed by regression of hand and/or communication skills, and subsequent development of hand stereotypies, while gait is often abnormal in those who are learning to walk.

Despite a wide phenotypic variability, RTT is commonly associated with epilepsy, sleep disturbances, and gastrointestinal dysfunction thus suggesting a link between RTT's gastrointestinal abnormalities and the gut microbiota.

RTT is associated with a dysbiosis of both the bacterial and fungal component of the gut microbiota, suggesting that MeCP2 loss-of-function can favour the establishment of a peculiar microbial community with altered production of short chain fatty acids (SCFAs) possibly contributing to the RTT gastrointestinal physiopathology.

Modulation of the systemic inflammatory response using pre- and post-biotics is advocated as a possible global therapeutic approach in neurological diseases such as Alzheimer's dementia.

Alpha-lactalbumin (ALAC), is the predominant whey protein in human milk, provides essential amino acids for protein synthesis in the developing neonates. Its supplementation in adults are associated with improved cognition, better memory and sleep. The bioactive properties of ALAC relate to antimicrobial activity, pre-biotic features and epithelial restoration via selective apoptosis activity. Moreover, the antibacterial peptides released from ALAC during digestion can exert immunostimulatory effects inducing phagocytic activity. Overall, ALAC shows reduction of inflammation and oxidative stress status as well as improvement of insulin resistance and increase in the synthesis of brain serotonin, a central nervous system neurotransmitter with well-known antiepileptic activity.

Butyrate, a bacterial metabolite and one of the main SCFAs, exhibits a broad range of pharmacological activities including microbiome modulating, anti-inflammatory, metabolic pathway regulating and anti-oxidant actions.

This body of knowledge supports testing pre- and post-biotics strategies for benefit in individuals with Rett syndrome with the goal of translating potential new treatments from experimental models to clinical practice. Results of this study could lead to the first approved pre- / post-biotics treatment for common co-morbidities in the disorder.

03

Conditions studied

  • Rett Syndrome
  • Dysbiosis
  • Epilepsy
  • Quality of Life

Keywords

  • Gut dysfunction
  • Inflammation
  • Alpha-lactalbumin
  • Butyrate
04

Who can participate

Ages eligible
3 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of classic/typical Rett syndrome (and proven loss-of-function mutation of the MeCP2 gene) with gastrointestinal dysfunction and/or positive history of epilepsy
  • Female gender (age > / = 3 years old)
  • Ability to obtain written from their parent(s)/legal guardian(s)
  • Stable medications for at least 4 weeks prior to the baseline visit.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis not fitting into the Rett syndrome consensus guidelines
  • Nonpathogenic MECP2 mutation or mutations in non-MECP2 genes (i.e., cyclin-dependent kinase 5, CDKL5; forkhead box protein G1, FOXG1)
  • Male gender
  • Percutaneous endoscopic gastrostomy (PEG) tube
  • Proven to one or more components of the dietary supplements (X-biotics)
  • Unstable concomitant medications less than 4 weeks prior to enrollment visit.
  • Concomitant antibiotic therapy at the enrollment. In the case of antibiotic therapy, a 4-weeks will be undertaken.
  • Rejection of the form by the parents/caregivers and/or lack of compliance to the Study procedures.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
28 participants (actual)

Study arms

  • Active comparator
    Pre- and post-biotic (ALAC, inulin, FOS, and sodium butyrate)

    The product (ALAC+butyrate+inulin+fructo oligosaccharides FOS) is a powder for oral suspension. Dosage is dependent on weight. For participants weighing \<50 kg, a 4 g dose (i.e., one 4 g sachet) is intended to be administered orally once a day after dissolving in water. For participants weighing ≥50 kg, a 4 g dose (i.e., 4 g sachets) is intended to be administered orally twice a day (12h interval) after dissolving in water.

    Dietary Supplement: ALAC, inulin, FOS, and sodium butyrate

  • Active comparator
    Post-biotic (sodium butyrate and zinc oxide)

    The product (sodium butyrate+ zinc oxide) is in the form of tablets. Dosage is dependent on weight. For participants weighing \<25 kg, one 380 mg tablet is intended to be administered orally twice a day . For participants weighing 25 to 40 kg, three 380 mg tablet dose is intended to be administered orally according to the 2+1 tablets per day schedule (12h interval). For participants weighing ≥40 kg, four 380 mg tablet dose is intended to be administered orally according to the 2+2 tablets per day schedule (12h interval).

    Dietary Supplement: Sodium butyrate and zinc oxide

Interventions

  • Dietary supplementALAC, inulin, FOS, and sodium butyrate

    Pre- and post-biotic supplementation will be administered for 3 month period (i.e. 12 weeks) given the filling out of a supplementation diary by parents/caregivers. At the scheduled visits/ phone contacts (i.e., baseline, 4 weeks and 12 weeks), systemic inflammation, intestinal inflammation, and gut microbiome characterization as well as treatment compliance, clinical and dietary intake will be assessed. A seizure diary will be provided to parents/caregivers in order to check the frequency and entity of the critical episodes. An EEG recording will be performed at enrollment (or within 6 months prior to the baseline visit).

  • Dietary supplementSodium butyrate and zinc oxide

    Drug pages: Butyric AcidStudies of Butyric AcidButyric Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Zinc OxideStudies of Zinc OxideZinc Oxide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Post-biotic supplementation will be administered for 3 month period (i.e. 12 weeks) given the filling out of a supplementation diary by parents/caregivers. At the scheduled visits/ phone contacts (i.e., baseline, 4 weeks and 12 weeks), systemic inflammation, intestinal inflammation, and gut microbiome characterization, as well as treatment compliance, clinical and dietary intake will be assessed. A seizure diary will be provided to parents/caregivers in order to check the frequency and entity of the critical episodes. An EEG recording will be performed at enrollment (or within 6 months prior to the baseline visit).

06

What researchers measure

Primary outcomes

  1. Systemic inflammation

    Change in circulating pro-inflammatory or change in anti-inflammatory cytokine levels

    Time frame: Change at 3 months from baseline of each interventional arm

  2. Gut inflammation

    Change in fecal calprotectin levels

    Time frame: Change at 3 months from baseline of each interventional arm

  3. Gut dysbiosis

    Change in intestinal microbiota biodiversity

    Time frame: Change at 3 months from baseline of each interventional arm

Secondary outcomes

  1. Epileptogenesis

    Change in frequency and/or severity of epileptic seizures (a seizure diary provided to parents/caregivers at the baseline visit)

    Time frame: Change at 3 months from baseline of each interventional arm

Other outcomes

  1. Quality of life and gastrointestinal health

    Change in well-being indices \[Quality of Life Inventory-Disability Questionnaire (QI-Disability), Gastrointestinal Health Questionnaire (GHQ), Bristol Stool Chart (BSC), Rome III scoring, Sleep Disturbance Scale for Children Questionnaire (SDSC)\] \[QI-Disability: lower scores indicate a worse outcome, BSC: type 1-2 indicate constipation, type 3-4 normal, and type 5-7 diarrhea), Rome III scoring: higher scores indicate a worse outcome, SDSC: higher scores indicate a worse outcome\]

    Time frame: Change at 3 months from baseline of each interventional arm

  2. Quality of life and illness severity

    Change in clinical severity \[Rett Syndrome Behaviour Questionnaire (RSBQ) and Motor Behavioural Assessment Scale (MBAS)\] (higher scores of RSBQ and MBAS indicate a worse outcome)

    Time frame: Change at 3 months from baseline of each interventional arm

07

Study locations

1 site
  • Policlinico "S. Maria alle Scotte" Azienda Ospedaliera Universitaria Senese
    Siena, 53100, Italy
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2022 to primary completion in Feb 2023, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2022
First posted
Jun 15, 2022
StartActual
Apr 1, 2022
Primary completionActual
Feb 28, 2023
CompletionActual
Feb 28, 2023
Last update
Apr 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05420805
Lead sponsor
Azienda Ospedaliera Universitaria Senese
Collaborators
Kolfarma s.r.l. - Italy, European Institute of Oncology
Responsible party
Claudio De Felice (Principal Investigator, Azienda Ospedaliera Universitaria Senese) — Principal investigator
First posted
Jun 15, 2022
Start date
Apr 1, 2022
Primary completion
Feb 28, 2023
Completion
Feb 28, 2023
Last update
Apr 18, 2023

Study contacts

Claudio De Felice, MD
principal investigator · Policlinico "S. Maria alle Scotte" Azienda Ospedaliera Universitaria Senese , 53100 Siena, Italy

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Butyric Acid · Zinc Oxide

Start the discussion